2.Oquendo, MA, Perez-Rodriguez, MM, Poh, E, et al. Life events: a complex role in the timing of suicidal behavior among depressed patients. Mol Psychiatry. 2014; 19(8): 902–909.
3.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
4.Zalsman, G, Hawton, K, Wasserman, D, et al. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016; 3(7): 646–659.
5.Hillhouse, TM, Porter, JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015; 23(1): 1–21.
7.Castelpietra, G, Gobbato, M, Valent, F, et al. Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005–2014. Eur J Clin Pharmacol. 2017; 73(7): 883–890.
8.Pratt, L, Brody, DJ, Gu, Q. Antidepressant use among persons aged 12 and over: United States, 2011–2014. NCHS Data Brief, No. 283. Hyattsville, MD: National Center for Health Statistics; 2017.
9.Organisation for Economic Co-operation and Development. Antidepressant consumption, 2000 and 2014 (or nearest year). In: Gautam, A, ed. Tackling Wasteful Spending on Health. Paris, France: OECD Publishing; 2017. http://dx.doi.org/10.1787/9789264266414-graph13-en. Accessed October 9, 2017.
11.Hammad, TA, Laughren, T, Racoosin, J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006; 63(3): 332–339.
13.Stone, M, Laughren, T, Jones, ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009; 339:b2880.
14.Hammad, TA, Laughren, TP, Racoosin, JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol. 2006; 26(2): 203–207.
15.Acharya, N, Rosen, AS, Polzer, JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006; 26(6): 587–594.
16.Pedersen, AG. Citalopram and suicidality in adult major depression and anxiety disorders. Nord J Psychiatry. 2006; 60(5): 392–399.
17.Pedersen, AG. Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol. 2005; 20(3): 139–143.
18.Gibbons, RD, Brown, CH, Hur, K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012; 69(6): 580–587.
19.Tollefson, GD, Fawcett, J, Winokur, G, et al. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann Clin Psychiatry. 1993; 5(4): 209–224.
20.Fillipov, G, Christens, PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability study in major depressive disorder. Paper presented at: 26th European College of Neuropsychopharmacology (ECNP) Congress; October 5–9, 2013; Barcelona, Spain.
21.Thase, ME, Gommoll, C, Chen, C, et al. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. CNS Spectr. 2017; 22(6): 475–483.
22.Kasper, S, Montgomery, SA, Moller, HJ, et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry. 2010; 11(1): 36–44.
23.Rihmer, Z, Gonda, X, Kapitany, B, et al. Suicide in Hungary: epidemiological and clinical perspectives. Ann Gen Psychiatry. 2013; 12(1): 21.
24.Cheung, K, Aarts, N, Noordam, R, et al. Antidepressant use and the risk of suicide: a population-based cohort study. J Affect Disord. 2015; 174: 479–484.
25.Posner, K, Brown, GK, Stanley, B, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12): 1266–1277.
26.Trintellix (vortioxetine) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals, America; 2017.
28.Bang-Andersen, B, Ruhland, T, Jorgensen, M, et al. Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206–3221.
29.Sanchez, C, Asin, KE, Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015; 145(Suppl C): 43–57.
30.Connolly, KR, Thase, ME. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother. 2016; 17(3): 421–431.
31.Baldwin, DS, Chrones, L, Florea, I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016; 30(3): 242–252.
32.Jain, R, Mahableshwarkar, AR, Jacobsen, PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(2): 313–321.
33.Mahableshwarkar, AR, Jacobsen, PL, Chen, Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217–226.
34.Henigsberg, N, Mahableshwarkar, AR, Jacobsen, P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7): 953–959.
35.Mahableshwarkar, AR, Jacobsen, PL, Chen, Y, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015; 232(12): 2061–2070.
36.Jacobsen, PL, Mahableshwarkar, AR, Serenko, M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5): 575–582.
37.Mahableshwarkar, AR, Jacobsen, PL, Serenko, M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5): 583–591.
38.Boulenger, JP, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29(3): 138–149.
39.Alvarez, E, Perez, V, Dragheim, M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589–600.
40.Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482–491.
41.Katona, C, Hansen, T, Olsen, CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215–223.
42.Alam, MY, Jacobsen, PL, Chen, Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014; 29(1): 36–44.
43.Jacobsen, PL, Harper, L, Chrones, L, et al. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2015; 30(5): 255–264.
44.U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. Silver Spring, MD: U.S. Food and Drug Administration; 2012.
45.Klepper, MJ, Cobert, B. Drug Safety Data: How to Analyze, Summarize, and Interpret to Determine Risk. Westfield, NJ: Jones and Bartlett Learning LLC; 2011.
46.Thase, ME, Edwards, J, Durgam, S, et al. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2017; 32(5): 281–288.
47.Grunebaum, MF, Ellis, SP, Duan, N, et al. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology. 2012; 37(3): 697–706.